Hepatitis D - Pipeline Insight, 2021

Hepatitis D - Pipeline Insight, 2021

  • May 2021 •
  • 60 pages •
  • Report ID: 5028063 •
  • Format: PDF
“Hepatitis D - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Hepatitis D pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Hepatitis D Understanding

Hepatitis D : Overview
Hepatitis D, also known as “delta hepatitis,” is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as “coinfection”) or get hepatitis D after first being infected with the hepatitis B virus (known as “superinfection”). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection.

"Hepatitis D - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis D pipeline landscape is provided which includes the disease overview and Hepatitis D treatment guidelines. The assessment part of the report embraces, in depth Hepatitis D commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis D collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis D R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis D.

Hepatitis D Emerging Drugs Chapters
This segment of the Hepatitis D report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis D Emerging Drugs
• Lonafarnib: Eiger Biopharmaceuticals
Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly. Lonafarnib has been dosed in over 120 HDV-infected patients across international academic centers and is in Phase 3 development for HDV with a single, pivotal trial. Lonafarnib has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Fast Track and now Breakthrough designation by U.S. FDA. Lonafarnib is not approved for any indication, and is licensed from Merck Sharp & Dohme Corp. (known as MSD outside of the United States and Canada).

• JNJ 73763989: Arrowhead Pharmaceuticals
JNJ 73763989 (formerly ARO HBV) is an RNA interference (RNAi) therapeutic, being developed by Arrowhead Pharmaceuticals for the treatment of patients with hepatitis B and hepatitis D infections.
Further product details are provided in the report……..

Hepatitis D: Therapeutic Assessment
This segment of the report provides insights about the different Hepatitis D drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Hepatitis D
There are approx. 4+ key companies which are developing the therapies for Hepatitis D. The companies which have their Hepatitis D drug candidates in the most advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.

• Phases
This report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis D: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis D therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis D drugs.

Hepatitis D Report Insights
• Hepatitis D Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatitis D Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Hepatitis D drugs?
• How many Hepatitis D drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis D?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis D therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis D and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Eiger Biopharmaceuticals
• Arrowhead Pharmaceuticals
• ContraVir Pharmaceuticals
• Antios Therapeutics
• PharmaEssentia
• REPLICor
• SomaGenics

Key Products
• Lonafarnib
• JNJ 73763989
• CRV 431
• ATI-2173
• Ropeginterferon Alfa-2b (P1101)
• REP 2165